SERAFLO HFA Inhaler

Salmeterol+Fluticasone Propionate

Composition : Each metered dose (Puff) contains Salmeterol BP 25 mcg as Salmeterol Xinafoate and Fluticasone Propionate BP 250 mcg.

Indication : This Inhaler is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short acting beta-2- agonist or, Patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.

Dosage and administration : Adults and adolescents 12 years and older : Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily. Or as directed by the registered physician.

Use in pregnancy and lactation : Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.

Packing : Each box contains one inhaler of 120 Puffs.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2022 Designed and Developed by ATI Limited.